Titlebook: Update of Non-Pharmacological Therapy for Heart Failure; Koichiro Kinugawa,Teruhiko Imamura Book 2020 Springer Nature Singapore Pte Ltd. 2

Lipohypertrophy

Gratulate

IABP/ECMO, and safety profile. Recently, the strategies are changing based on large clinical trials. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock is rapidly increasing, with the improvement of device technology and practical management. VA-ECMO can ac

易怒

Impella,entricle to the ascending aorta, improving systemic circulation and end-organ dysfunction and unloading left ventricle in patients with cardiogenic shock. Impella has not shown a significant survival benefit in patients with cardiogenic shock compared with conventional intra-aortic balloon pumping i

支形吊燈

MitraClip,ve repair or replacement might be effective in some of the cases, but it has been challenging particularly for the high-risk cases. Recently, percutaneous edge-to-edge mitral valve repair using the MitraClip system, which enables us to approach the mitral valve at relatively low risk, has been devel

harmony

裁決

感情脆弱

披肩

Regenerative Medicine for Heart Failure: A Comprehensive Overview of Clinical Studies, Current Chaletal myoblasts in HF, a number of preclinical and clinical studies have been conducted, which support the ability of various stem cell populations to improve cardiac function and reduce the infarct size in HF. However, it is still too early in this new era of regenerative cell therapy as the novel m

Prologue

領(lǐng)巾